Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Fluidigm, Verinata; Boehringer Ingelheim, Structural Genomics Consortium; Danaher; Sigma-Aldrich; More

NEW YORK (GenomeWeb News) – Fluidigm said that it could receive up to an additional $3.2 million in proceeds from its minority stake in Verinata, acquired by Illumina in February for up to $450 million. In March Fluidigm received proceeds of $3.1 million in exchange for its ownership in Verinata, resulting in a gain of $1.8 million, it said in its Form 10-Q filed this week. Fluidigm added that it could receive the additional $3.2 million in proceeds if "certain milestone payments become payable."


Boehringer Ingelheim has joined the Structural Genomics Consortium, which seeks to encourage research into protein structures and epigenetics for the development of new therapies for previously incurable diseases. As a member of the consortium, Boehringer will provide funding for precompetitive drug research.


Danaher's board approved a regular quarterly dividend of $.025 per share, payable on July 26 to shareholders of record on June 28.


Sigma-Aldrich's board approved a quarterly cash dividend of $.215 per share, payable on June 14 to shareholders of record on May 31.


Synthetic biology company Intrexon, which recently raised $150 million in a preferred investment round, this week realigned its industry markets to focus on four sectors: Health, Food, Energy, and Environment. The market alignment is aimed at accelerating business development across all of the company's key market sectors using its exclusive channel collaboration model, it said.


German analytical instruments company Analytik Jena said that revenues in its fiscal second quarter were down 1 percent year over year. For the three months ended March 31, the company recorded €22.6 million ($29.7 million) in revenues, compared to €22.9 million in the second quarter of 2012.

Profit during the quarter was €404,000, or €.06 per share, compared to a profit of €585,000, or €.09 per share, a year ago.

R&D expenses of €2.0 million were up 5 percent from €1.9 million a year ago, while SG&A costs narrowed 6 percent to €1.7 million from €1.8 million.


Firefly BioWorks awarded three grants to researchers in the microRNA field. The winners of the Firefly Frontiers Grants are Charles Vanderburg of Massachusetts General Hospital; Elena Flowers of the University of California, San Francisco; and Matthias Hackl of the University of Natural Resources and Life Sciences in Vienna. Each winner receives $10,000 to be used fo Firefly's products.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more